Search

Displaying results 3201 - 3210 of 3732 in total
  1. Drug

    Cilobradine

    go.drugbank.com/drugs/DB20039
    Investigational

    Cilobradine is under investigation in clinical trial NCT02264041 (Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine).

  2. Drug

    Nafimidone

    go.drugbank.com/drugs/DB20780
    Experimental

    Nafimidone is a small molecule drug. Nafimidone has a monoisotopic molecular weight of 236.09 Da.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors
  3. Drug

    Fantofarone

    go.drugbank.com/drugs/DB20875
    Experimental

    Fantofarone is a small molecule drug. Fantofarone has a monoisotopic molecular weight of 550.25 Da.

    Categories: P-glycoprotein inhibitors
  4. Drug

    Oxeclosporin

    go.drugbank.com/drugs/DB21134
    Experimental

    Oxeclosporin is a small molecule drug. The usage of the INN stem '-(clo)sporin' in the name indicates that Oxeclosporin is a cyclosporine derivative. Oxeclosporin has a monoisotopic molecular weight of 1261.86 Da.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Befetupitant

    go.drugbank.com/drugs/DB21149
    Experimental

    The usage of the INN stem '-pitant' in the name indicates that Befetupitant is a neurokinin NK1​ (substance P) receptor antagonist. Befetupitant has a monoisotopic molecular weight of 565.22 Da.

  6. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    Oveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1). … [L64068,L64069] It is the first orexin receptor agonist approved by the FDA and the first medicine to treat NT1 by targeting its underlying cause rather than individual symptoms.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Fosrolapitant

    go.drugbank.com/drugs/DB21723
    Investigational

    The usage of the INN stem '-pitant' in the name indicates that Fosrolapitant is a neurokinin NK1​ (substance P) receptor antagonist. Fosrolapitant has a monoisotopic molecular weight of 654.16 Da.

  8. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    [L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. … [A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Althou...

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  10. Drug

    Heparin

    go.drugbank.com/drugs/DB01109
    ApprovedInvestigational

    Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibl...

    Products: Hep-Lock U/P